Summary
5.78 -0.19(-3.18%)07/05/2024
Solid Biosciences Inc (SLDB)
Solid Biosciences Inc (SLDB)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.18 | 5.25 | -27.39 | -52.23 | 3.99 | 14.75 | -92.39 | -98.23 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.78 | |
| Open | 5.98 | |
| High | 5.98 | |
| Low | 5.77 | |
| Volume | 82,070 | |
| Change | -0.19 | |
| Change % | -3.18 | |
| Avg Volume (20 Days) | 777,218 | |
| Volume/Avg Volume (20 Days) Ratio | 0.11 | |
| 52 Week Range | 1.81 - 15.05 | |
| Price vs 52 Week High | -61.59% | |
| Price vs 52 Week Low | 219.34% | |
| Range | 1.53 | |
| Gap Up/Down | -0.28 | |
Fundamentals | ||
| Market Capitalization (Mln) | 229 | |
| EBIDTA | -96,527,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 9.58 | |
| Book Value | 2.0250 | |
| Earnings Per Share | -0.7940 | |
| EPS Estimate Current Quarter | -0.2000 | |
| EPS Estimate Next Quarter | -0.2200 | |
| EPS Estimate Current Year | -0.7200 | |
| EPS Estimate Next Year | -0.8300 | |
| Diluted EPS (TTM) | -0.7940 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -7.1612 | |
| Return on asset (TTM) | -0.3236 | |
| Return on equity (TTM) | -0.6103 | |
| Revenue TTM | 10,466,000 | |
| Revenue per share TTM | 0.1110 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.8691 | |
| Revenue Enterprise Value | 0.3951 | |
| EBITDA Enterprise Value | 0.4637 | |
| Shares | ||
| Shares Outstanding | 110,296,000 | |
| Shares Float | 42,560,866 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 12.74 | |
| Institutions (%) | 70.66 | |
07/01 16:19 EST - globenewswire.com
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
06/04 16:00 EST - globenewswire.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 30,949 restricted stock units (“RSUs”) to four newly hired employees.
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 30,949 restricted stock units (“RSUs”) to four newly hired employees.
05/20 06:00 EST - investorplace.com
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.
05/15 12:53 EST - investorplace.com
SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024
Solid Biosciences (NASDAQ: SLDB ) just reported results for the first quarter of 2024. Solid Biosciences reported earnings per share of -64 cents.
SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024
Solid Biosciences (NASDAQ: SLDB ) just reported results for the first quarter of 2024. Solid Biosciences reported earnings per share of -64 cents.
05/15 07:52 EST - globenewswire.com
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 —
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 —
04/10 19:32 EST - seekingalpha.com
Buy Solid Biosciences: Unpacking Its Main Value Driver
Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation.
Buy Solid Biosciences: Unpacking Its Main Value Driver
Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation.
04/05 04:54 EST - finbold.com
How this insider trader nailed every single stock trade
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
How this insider trader nailed every single stock trade
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
04/02 11:36 EST - zacks.com
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
04/01 07:45 EST - globenewswire.com
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003, the company's next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003, the company's next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.
03/28 11:31 EST - investors.com
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
03/13 07:44 EST - globenewswire.com
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 —
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 —
02/18 11:20 EST - 24/7 Wall Street
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
02/12 08:53 EST - 247wallst.com
Another Huge Buffett Purchase Highlights Recent Insider Buying
The most notable of insider purchases in the past week or so is again legendary investor Warren Buffett boosting the Berkshire Hathaway stake in his favorite petroleum company.
Another Huge Buffett Purchase Highlights Recent Insider Buying
The most notable of insider purchases in the past week or so is again legendary investor Warren Buffett boosting the Berkshire Hathaway stake in his favorite petroleum company.
01/24 11:29 EST - marketwatch.com
Joe Lewis, billionaire owner of Tottenham Hotspur football club, pleads guilty to insider trading
British billionaire Joe Lewis, who owns the Tottenham Hotspur football club, has pleaded guilty to insider trading charges in New York, after prosecutors had charged him with sharing secret stock tips with his pilots, girlfriends and assistants for years.
Joe Lewis, billionaire owner of Tottenham Hotspur football club, pleads guilty to insider trading
British billionaire Joe Lewis, who owns the Tottenham Hotspur football club, has pleaded guilty to insider trading charges in New York, after prosecutors had charged him with sharing secret stock tips with his pilots, girlfriends and assistants for years.
01/20 10:49 EST - 24/7 Wall Street
More Big Warren Buffett Purchases Highlight Recent Insider Buying
The number of notable insider purchases in mid-January may have been somewhat small, but a couple from the Oracle of Omaha made headlines.
More Big Warren Buffett Purchases Highlight Recent Insider Buying
The number of notable insider purchases in mid-January may have been somewhat small, but a couple from the Oracle of Omaha made headlines.
01/17 12:31 EST - zacks.com
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
01/16 23:01 EST - seekingalpha.com
Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression.
Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression.